182 related articles for article (PubMed ID: 29934866)
1. Backbone assignment of the apo-form of the human C-terminal domain of UDP-glucuronosyltransferase 1A (UGT1A).
Osborne MJ; Coutinho de Oliveira L; Volpon L; Borden KLB
Biomol NMR Assign; 2018 Oct; 12(2):315-318. PubMed ID: 29934866
[TBL] [Abstract][Full Text] [Related]
2. Structural and functional studies of UDP-glucuronosyltransferases.
Radominska-Pandya A; Czernik PJ; Little JM; Battaglia E; Mackenzie PI
Drug Metab Rev; 1999 Nov; 31(4):817-99. PubMed ID: 10575553
[TBL] [Abstract][Full Text] [Related]
3. The crystal structure of human UDP-glucuronosyltransferase 2B7 C-terminal end is the first mammalian UGT target to be revealed: the significance for human UGTs from both the 1A and 2B families.
Radominska-Pandya A; Bratton SM; Redinbo MR; Miley MJ
Drug Metab Rev; 2010 Feb; 42(1):133-44. PubMed ID: 19821783
[TBL] [Abstract][Full Text] [Related]
4.
Sulekha A; Osborne MJ; Gasiorek J; Borden KLB
Biomol NMR Assign; 2023 Jun; 17(1):67-73. PubMed ID: 36757531
[TBL] [Abstract][Full Text] [Related]
5.
Osborne MJ; Rahardjo AK; Volpon L; Borden KLB
Biomol NMR Assign; 2021 Oct; 15(2):323-328. PubMed ID: 33870481
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7.
Miley MJ; Zielinska AK; Keenan JE; Bratton SM; Radominska-Pandya A; Redinbo MR
J Mol Biol; 2007 Jun; 369(2):498-511. PubMed ID: 17442341
[TBL] [Abstract][Full Text] [Related]
7. Oligomerization of the UDP-glucuronosyltransferase 1A proteins: homo- and heterodimerization analysis by fluorescence resonance energy transfer and co-immunoprecipitation.
Operaña TN; Tukey RH
J Biol Chem; 2007 Feb; 282(7):4821-4829. PubMed ID: 17179145
[TBL] [Abstract][Full Text] [Related]
8. Insights into the UDP-sugar selectivities of human UDP-glycosyltransferases (UGT): a molecular modeling perspective.
Nair PC; Meech R; Mackenzie PI; McKinnon RA; Miners JO
Drug Metab Rev; 2015 Aug; 47(3):335-45. PubMed ID: 26289097
[TBL] [Abstract][Full Text] [Related]
9. Human UDP-glucuronosyltransferase 2B7.
Radominska-Pandya A; Little JM; Czernik PJ
Curr Drug Metab; 2001 Sep; 2(3):283-98. PubMed ID: 11513331
[TBL] [Abstract][Full Text] [Related]
10. Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A.
Li D; Fournel-Gigleux S; Barré L; Mulliert G; Netter P; Magdalou J; Ouzzine M
J Biol Chem; 2007 Dec; 282(50):36514-24. PubMed ID: 17956868
[TBL] [Abstract][Full Text] [Related]
11. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification.
Rowland A; Miners JO; Mackenzie PI
Int J Biochem Cell Biol; 2013 Jun; 45(6):1121-32. PubMed ID: 23500526
[TBL] [Abstract][Full Text] [Related]
12. Medicinal Chemistry and NMR Driven Discovery of Novel UDP-glucuronosyltransferase 1A Inhibitors That Overcome Therapeutic Resistance in Cells.
Osborne MJ; Sulekha A; Culjkovic-Kraljacic B; Gasiorek J; Ruediger E; Jolicouer E; Marinier A; Assouline S; Borden KLB
J Mol Biol; 2024 Jan; 436(2):168378. PubMed ID: 38043731
[TBL] [Abstract][Full Text] [Related]
13. Activation of Cryptic Donor Splice Sites within the UDP-Glucuronosyltransferase (UGT)1A First-Exon Region Generates Variant Transcripts That Encode UGT1A Proteins with Truncated Aglycone-Binding Domains.
Hu DG; Marri S; Hulin JA; Ansaar R; Mackenzie PI; McKinnon RA; Meech R
Drug Metab Dispos; 2024 May; 52(6):526-538. PubMed ID: 38565302
[TBL] [Abstract][Full Text] [Related]
14. Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases.
Zhou J; Zhang J; Xie W
Curr Drug Metab; 2005 Aug; 6(4):289-98. PubMed ID: 16101569
[TBL] [Abstract][Full Text] [Related]
15. In silico insights: chemical and structural characteristics associated with uridine diphosphate-glucuronosyltransferase substrate selectivity.
Smith PA; Sorich MJ; McKinnon RA; Miners JO
Clin Exp Pharmacol Physiol; 2003 Nov; 30(11):836-40. PubMed ID: 14678246
[TBL] [Abstract][Full Text] [Related]
16. Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes.
Dong D; Ako R; Hu M; Wu B
Xenobiotica; 2012 Aug; 42(8):808-20. PubMed ID: 22385482
[TBL] [Abstract][Full Text] [Related]
17. Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes.
Osborne MJ; Coutinho de Oliveira L; Volpon L; Zahreddine HA; Borden KLB
J Mol Biol; 2019 Jan; 431(2):258-272. PubMed ID: 30428301
[TBL] [Abstract][Full Text] [Related]
18. Photoaffinity labeling studies of the human recombinant UDP-glucuronosyltransferase, UGT1*6, with 5-azido-UDP-glucuronic acid.
Battaglia E; Nowell S; Drake RR; Magdalou J; Fournel-Gigleux S; Senay C; Radominska A
Drug Metab Dispos; 1997 Apr; 25(4):406-11. PubMed ID: 9107538
[TBL] [Abstract][Full Text] [Related]
19. Potential genoprotective role for UDP-glucuronosyltransferases in chemical carcinogenesis: initiation of micronuclei by benzo(a)pyrene and benzo(e)pyrene in UDP-glucuronosyltransferase-deficient cultured rat skin fibroblasts.
Vienneau DS; DeBoni U; Wells PG
Cancer Res; 1995 Mar; 55(5):1045-51. PubMed ID: 7866987
[TBL] [Abstract][Full Text] [Related]
20. Use of cloned and expressed human liver UDP-glucuronosyltransferases for analysis of drug glucuronide formation and assessment of drug toxicity.
Burchell B; Ebner T; Baird S; Bin Senafi S; Clarke D; Brierley C; Sutherland L
Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):19-23. PubMed ID: 7698078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
